EMILY BROZGAL: Open Payments
NPI 1881018265 · KINGWOOD, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,397 in 59 payments from 15 companies in 2025. Trend: 2023 $21 · 2024 $253 · 2025 $1,397
Food & beverage: $1,397
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $263 |
| Teva Pharmaceuticals USA, Inc. | 3 | $149 |
| Neurocrine BioSciences, Inc. | 8 | $149 |
| Alkermes, Inc. | 7 | $130 |
| Lundbeck LLC | 5 | $119 |
| Otsuka America Pharmaceutical, Inc. | 5 | $112 |
| ABBVIE INC. | 4 | $99 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $97 |
| Axsome Therapeutics, Inc. | 4 | $84 |
| E.R. Squibb & Sons, L.L.C. | 3 | $78 |
Products named: CAPLYTA, REXULTI, INGREZZA, ARISTADA, UZEDY, VRAYLAR, TRINTELLIX, Auvelity.
Industry payments across TX — which companies pay providers there.
